RÉSUMÉ
BACKGROUND: Understanding patients' decision control preferences is important in providing quality cancer care. Patients' decisional control preference can be either active (patients prefer to make decisions themselves), shared (collaborative between patient, their physician, and/or family), or passive (patients prefer that the decisions are made by either the physician and/or their family). AIM: To determine the frequency and predictors of passive decision control preferences among advanced cancer patients. We also determined the concordance between actual decision-making and decision control preferences and its association with patient satisfaction. DESIGN: In this cross-sectional survey of advanced cancer patients referred to palliative care across 11 countries, we evaluated sociodemographic variables, Control Preference Scale, and satisfaction with the decisions and care. RESULTS: A total of 1490 participants were evaluable. Shared, active, and passive decision control preferences were 33%, 44%, and 23%, respectively. Passive decision control preferences (odds ratio, p value) was more frequent in India (4.34, <0.001), Jordan (3.41, <0.001), and France (3.27, <0.001). Concordance between the actual decision-making and decision control preferences was highest in the United States ( k = 0.74) and lowest in Brazil (0.34). Passive decision control preference was significantly associated with (odds ratio per point, p value) better performance status (0.99/point, 0.017), higher education (0.64, 0.001), and country of origin (Brazil (0.26, <0.0001), Singapore (0.25, 0.0003), South Africa (0.32, 0.0002), and Jordan (2.33, 0.0037)). CONCLUSION: Passive decision control preferences were less common (23%) than shared and active decision control preference even among developing countries. Significant predictors of passive decision control preferences were performance status, education, and country of origin.
Sujet(s)
Prise de décision , Tumeurs/anatomopathologie , Participation des patients , Préférence des patients , Sujet âgé , Sujet âgé de 80 ans ou plus , Études transversales , Femelle , Humains , Mâle , Adulte d'âge moyen , Satisfaction des patients , Qualité des soins de santé , Enquêtes et questionnairesRÉSUMÉ
BACKGROUND: There are limited data on illness understanding and perception of cure among advanced cancer patients around the world. The aim of the study was to determine the frequency and factors associated with inaccurate perception of curability among advanced cancer patients receiving palliative care across the globe. MATERIALS AND METHODS: Secondary analysis of a study to understand the core concepts in end-of-life care among advanced cancer patients receiving palliative care from 11 countries across the world. Advanced cancer patients were surveyed using a Patient Illness Understanding survey and Control Preference Scale. Descriptive statistics and multicovariate logistic regression analysis were performed. RESULTS: Fifty-five percent (763/1,390) of patients receiving palliative care inaccurately reported that their cancer is curable. The median age was 58, 55% were female, 59% were married or had a partner, 48% were Catholic, and 35% were college educated. Sixty-eight percent perceived that the goal of therapy was "to get rid of their cancer," and 47% perceived themselves as "seriously ill." Multicovariate logistic regression analysis shows that accurate perception of curability was associated with female gender (odds ratio [OR] 0.73, p = .027), higher education (OR 0.37, p < .0001), unemployment status (OR 0.69, p = .02), and being from France (OR 0.26, p < .0001) and South Africa (OR 0.52, p = .034); inaccurate perception of curability was associated with better Karnofsky performance status (OR 1.02 per point, p = .0005), and being from Philippines (OR 15.49, p < .0001), Jordan (OR 8.43, p < .0001), Brazil (OR 2.17, p = .0037), and India (OR 2.47, p = .039). CONCLUSION: Inaccurate perception of curability in advanced cancer patients is 55% and significantly differs by gender, education, performance status, employment status, and country of origin. Further studies are needed to develop strategies to reduce this misperception of curability in advanced cancer patients. IMPLICATIONS FOR PRACTICE: The findings of this study indicate that inaccurate perception of curability among advanced cancer patients is 55%. Inaccurate perception of curability significantly differs by gender, education, performance status, employment status, and country of origin. There is great need to facilitate improved patient-physician communication so as to improve health care outcomes and patient satisfaction.
Sujet(s)
Attitude envers la santé , Tumeurs/psychologie , Tumeurs/thérapie , Soins palliatifs/psychologie , Adulte , Sujet âgé , Communication , Prise de décision , Femelle , Humains , Coopération internationale , Mâle , Adulte d'âge moyen , Tumeurs/anatomopathologie , Relations médecin-patient , Pronostic , Soins terminaux/psychologieRÉSUMÉ
A novel series of N-aryl-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamides was identified as transient receptor potential melastatin 8 (TRPM8) channel blockers through analogue-based rational design, synthesis and screening. Details of the synthesis, effect of aryl groups and their substituents on in-vitro potency were studied. The effects of selected functional groups on the 4-position of the chromene ring were also studied, which showed interesting results. The 4-hydroxy derivatives showed excellent potency and selectivity. Optical resolution and screening of alcohols revealed that (R)-(-)-isomers were in general more potent than the corresponding (S)-(+)-isomers. The isomer (R)-(-)-10e (IC50: 8.9nM) showed a good pharmacokinetic profile upon oral dosing at 10mg/kg in Sprague-Dawley (SD) rats. The compound (R)-(-)-10e also showed excellent efficacy in relevant rodent models of neuropathic pain.
Sujet(s)
Amides/composition chimique , Analgésiques/synthèse chimique , Pipéridines/composition chimique , Spiranes/composition chimique , Canaux cationiques TRPM/antagonistes et inhibiteurs , Administration par voie orale , Amides/pharmacocinétique , Amides/usage thérapeutique , Analgésiques/pharmacocinétique , Analgésiques/usage thérapeutique , Animaux , Modèles animaux de maladie humaine , Période , Mâle , Souris , Souris de lignée C57BL , Névralgie/traitement médicamenteux , Liaison aux protéines , Rats , Rat Sprague-Dawley , Stéréoisomérie , Relation structure-activité , Canaux cationiques TRPM/métabolismeRÉSUMÉ
Long-chain PUFA (LC-PUFA) are important for fetal and neonatal brain development. However, their accretion in the brain is compromised during maternal protein restriction. Hence, we investigated the effect of maternal supplementation with n-3 DHA plus n-6 arachidonic acid (ARA) at a low protein level (9 %) on offspring brain fatty acid accretion using Wistar rats (nine rats per group) randomly fed a control (C), a low-protein (LP) or a low-protein DHA + ARA-supplemented (LPS) diet during gestation and lactation. At birth, pups from the LPS group had the highest brain DHA and n-3 fatty acid levels (P = 0·001), whereas pups from the LP group had the highest MUFA (P = 0·05) but the lowest DHA and total n-3 PUFA levels (P = 0·000). During lactation, pups from the LPS group accrued significantly more α-linolenic acid (P = 0·003), EPA (P = 0·02) and DHA (P = 0·000) in brain lipids than pups from the LP group, whereas brain lipids of pups from the LP group had markedly increased levels of the n-3 deficiency marker docosapentaenoic acid and n-6:n-3 ratio (P = 0·000). Owing to supplementation, milk from LPS dams had the highest DHA and ARA, but lower SCFA and medium-chain fatty acids as compared with milk from C and LP dams during early lactation, but normalised by mid-lactation. To conclude, adverse effects of restricted maternal protein intake on LC-PUFA accretion in the brain of offspring were ameliorated by alterations in maternal milk fatty acid profile due to supplementation. Results underscore the importance of LC-PUFA for protein-deficient mothers during gestation as well as lactation to achieve the optimum brain LC-PUFA status of progeny.
RÉSUMÉ
OBJECTIVE: Parental history of hypertension, a commonly occurring nonmodifiable genetic risk factor, was examined for its influence on cutoff for body mass index (BMI) for identifying risk of hypertension. DESIGN: Data on BMI, body fat (%), blood pressure (BP), parental history of hypertension, and lifestyle factors were collected through a cross-sectional study. SETTING: Pune City, Maharashtra, India. SUBJECTS: Urban Indian adults (330 men and 306 women, aged 30-60 years). RESULTS: Age-related increases in prevalence of obesity and of hypertension (BP ≥ 140/90 mmHg or antihypertensive medication) were significant (p < 0.01 for all) in both sexes. Among nonobese subjects, age-adjusted systolic (SBP) and diastolic (DBP) blood pressure levels were significantly (p < 0.01) higher for those with positive parental history than for those without parental history, in both sexes. Adjusted odds ratios showed that obesity or positive parental history when considered in isolation increased the risk of hypertension (by 3 times in men and 5 times in women), while the presence of both increased it further (by 4 times in men and 10 times in women), indicating their synergistic influence. Further, the BMI cutoff obtained from receiver operating characteristic (ROC) analysis was lower by 1 to 1.5 units for subjects with parental history than for those without parental history, across different levels of sensitivity. CONCLUSIONS: Positive parental history lowers the BMI risk cutoff for hypertension. The implication is that parental history could be an important aid in developing preventive strategy for timely and early screening of individuals at risk of hypertension in many Asian populations in similar settings.
Sujet(s)
Indice de masse corporelle , Hypertension artérielle/génétique , Obésité/génétique , Adulte , Pression sanguine , Femelle , Prédisposition génétique à une maladie , Humains , Hypertension artérielle/épidémiologie , Hypertension artérielle/étiologie , Inde/épidémiologie , Mâle , Adulte d'âge moyen , Obésité/complications , Obésité/épidémiologie , Odds ratio , Parents , Prévalence , Courbe ROC , Valeurs de référence , Facteurs de risque , Facteurs sexuels , Santé en zone urbaineRÉSUMÉ
Osteoporosis is an important and often overlooked problem in men. Although the lifetime risk of hip fracture is lower in men than in women, men are twice as likely to die after a hip fracture. Bone mineral density measurement with a T-score of -2.5 or less indicates osteoporosis. The American College of Physicians recommends beginning periodic osteoporosis risk assessment in men before 65 years of age and performing dual-energy x-ray absorptiometry for men at increased risk of osteoporosis who are candidates for drug therapy. All men diagnosed with osteoporosis should be evaluated for secondary causes of bone loss. The decision regarding treatment of osteoporosis should be based on clinical evaluation, diagnostic workup, fracture risk assessments, and bone mineral density measurements. Pharmacotherapy is recommended for men with osteoporosis and for high-risk men with low bone mass (osteopenia) with a T-score of -1 to -2.5. Bisphosphonates are the first-line agents for treating osteoporosis in men. Teriparatide (i.e., recombinant human parathyroid hormone) is an option for men with severe osteoporosis. Testosterone therapy is beneficial for men with osteoporosis and hypogonadism. Adequate intake of calcium and vitamin D should be encouraged in all men to maintain bone mass. Men should be educated regarding lifestyle measures, which include weight-bearing exercise, limiting alcohol consumption, and smoking cessation. Fall prevention strategies should be implemented in older men at risk of falls.
Sujet(s)
Ostéoporose/diagnostic , Ostéoporose/prévention et contrôle , Dorsalgie/étiologie , Taille , Fractures osseuses/étiologie , Humains , Mâle , Ostéoporose/traitement médicamenteux , Posture , Facteurs de risqueRÉSUMÉ
Menopause is the permanent cessation of menstruation resulting from the loss of ovarian and follicular activity. It usually occurs when women reach their early 50s. Vasomotor symptoms and vaginal dryness are frequently reported during menopause. Estrogen is the most effective treatment for management of hot flashes and night sweats. Local estrogen is preferred for vulvovaginal symptoms because of its excellent therapeutic response. Bone mineral density screening should be performed in all women older than 65 years, and should begin sooner in women with additional risk factors for osteoporotic fractures. Adequate intake of calcium and vitamin D should be encouraged for all postmenopausal women to reduce bone loss. Coronary artery disease is the leading cause of death in women. Postmenopausal women should be counseled regarding lifestyle modification, including smoking cessation and regular physical activity. All women should receive periodic measurement of blood pressure and lipids. Appropriate pharmacotherapy should be initiated when indicated. Women should receive breast cancer screening every one to two years beginning at age 40, as well as colorectal cancer screening beginning at age 50. Women younger than 65 years who are sexually active and have a cervix should receive routine cervical cancer screening with Papanicolaou smear. Recommended immunizations for menopausal women include an annual influenza vaccine, a tetanus and diphtheria toxoid booster every 10 years, and a one-time pneumococcal vaccine after age 65 years.
Sujet(s)
Prestations des soins de santé/méthodes , Post-ménopause/physiologie , Adulte , Sujet âgé , Tumeurs du sein/prévention et contrôle , Calcium/administration et posologie , Tumeurs colorectales/prévention et contrôle , Maladie coronarienne/prévention et contrôle , Exercice physique , Femelle , Humains , Immunisation , Adulte d'âge moyen , Ostéoporose/prévention et contrôle , Fumer/effets indésirables , Tumeurs du col de l'utérus/prévention et contrôle , Vitamine D/administration et posologieRÉSUMÉ
Gastrointestinal complications of diabetes include gastroparesis, intestinal enteropathy (which can cause diarrhea, constipation, and fecal incontinence), and nonalcoholic fatty liver disease. Patients with gastroparesis may present with early satiety, nausea, vomiting, bloating, postprandial fullness, or upper abdominal pain. The diagnosis of diabetic gastroparesis is made when other causes are excluded and postprandial gastric stasis is confirmed by gastric emptying scintigraphy. Whenever possible, patients should discontinue medications that exacerbate gastric dysmotility; control blood glucose levels; increase the liquid content of their diet; eat smaller meals more often; discontinue the use of tobacco products; and reduce the intake of insoluble dietary fiber, foods high in fat, and alcohol. Prokinetic agents (e.g., metoclopramide, erythromycin) may be helpful in controlling symptoms of gastroparesis. Treatment of diabetes-related constipation and diarrhea is aimed at supportive measures and symptom control. Nonalcoholic fatty liver disease is common in persons who are obese and who have diabetes. In persons with diabetes who have elevated hepatic transaminase levels, it is important to search for other causes of liver disease, including hepatitis and hemochromatosis. Gradual weight loss, control of blood glucose levels, and use of medications (e.g., pioglitazone, metformin) may normalize hepatic transaminase levels, but the clinical benefit of aggressively treating nonalcoholic fatty liver disease is unknown. Controlling blood glucose levels is important for managing most gastrointestinal complications.
Sujet(s)
Antiémétiques/usage thérapeutique , Complications du diabète/physiopathologie , Stéatose hépatique/étiologie , Vidange gastrique , Gastroparésie , Métoclopramide/usage thérapeutique , Algorithmes , Complications du diabète/classification , Stéatose hépatique/physiopathologie , Vidange gastrique/effets des médicaments et des substances chimiques , Vidange gastrique/physiologie , Gastroparésie/classification , Gastroparésie/étiologie , Gastroparésie/physiopathologie , HumainsRÉSUMÉ
Parkinson's disease is a common neurodegenerative disorder that can cause significant disability and decreased quality of life. The cardinal physical signs of the disease are distal resting tremor, rigidity, bradykinesia, and asymmetric onset. Levodopa is the primary treatment for Parkinson's disease; however, its long-term use is limited by motor complications and drug-induced dyskinesia. Dopamine agonists are options for initial treatment and have been shown to delay the onset of motor complications. However, dopamine agonists are inferior to levodopa in controlling motor symptoms. After levodopa-related motor complications develop in advanced Parkinson's disease, it is beneficial to initiate adjuvant therapy with dopamine agonists, catechol O-methyltransferase inhibitors, or monoamine oxidase-B inhibitors. Deep brain stimulation of the subthalamic nucleus has been shown to ameliorate symptoms in patients with advanced disease. Depression, dementia, and psychosis are common psychiatric problems associated with Parkinson's disease. Psychosis is usually drug induced and can be managed initially by reducing antiparkinsonian medications. The judicious use of psychoactive agents may be necessary. Consultation with a subspecialist is often required.
Sujet(s)
Maladie de Parkinson/diagnostic , Maladie de Parkinson/thérapie , Algorithmes , Antiparkinsoniens/usage thérapeutique , Inhibiteurs de la catéchol O-méthyltransférase , Diagnostic différentiel , Agonistes de la dopamine/usage thérapeutique , Humains , Inhibiteurs de la monoamine oxydase/usage thérapeutique , Neuroprotecteurs/usage thérapeutique , Maladie de Parkinson/complicationsRÉSUMÉ
The incidence of hip fracture is expected to increase as the population ages. One in five persons dies in the first year after sustaining a hip fracture, and those who survive past one year may have significant functional limitation. Although surgery is the main treatment for hip fracture, family physicians play a key role as patients' medical consultants. Surgical repair is recommended for stable patients within 24 to 48 hours of hospitalization. Antibiotic prophylaxis is indicated to prevent infection after surgery. Thromboprophylaxis has become the standard of care for management of hip fracture. Effective agents include unfractionated heparin, low-molecular-weight heparin, fondaparinux, and warfarin. Optimal pain control, usually with narcotic analgesics, is essential to ensure patient comfort and to facilitate rehabilitation. Rehabilitation after hip fracture surgery ideally should start on the first postoperative day with progression to ambulation as tolerated. Indwelling urinary catheters should be removed within 24 hours of surgery. Prevention, early recognition, and treatment of contributing factors for delirium also are crucial. Interventions to help prevent future falls, exercise and balance training in ambulatory patients, and the treatment of osteoporosis are important strategies for the secondary prevention of hip fracture.
Sujet(s)
Fractures de la hanche/chirurgie , Rôle médical , Médecins de famille , Complications postopératoires/prévention et contrôle , Chutes accidentelles/prévention et contrôle , Antibioprophylaxie , Délire avec confusion/étiologie , Délire avec confusion/prévention et contrôle , Fractures de la hanche/diagnostic , Humains , Ostéoporose/prévention et contrôle , Mesure de la douleur , Prévention secondaire , Rétention d'urine/étiologie , Rétention d'urine/prévention et contrôle , Infections urinaires/étiologie , Infections urinaires/prévention et contrôle , Thrombose veineuse/étiologie , Thrombose veineuse/prévention et contrôleRÉSUMÉ
Falls are one of the most common geriatric syndromes threatening the independence of older persons. Between 30 and 40 percent of community-dwelling adults older than 65 years fall each year, and the rates are higher for nursing home residents. Falls are associated with increased morbidity, mortality, and nursing home placement. Most falls have multiple causes. Risk factors for falls include muscle weakness, a history of falls, use of four or more prescription medications, use of an assistive device, arthritis, depression, age older than 80 years, and impairments in gait, balance, cognition, vision, and activities of daily living. Physicians caring for older patients should ask about any falls that have occurred in the past year. Assessment should include evaluating the circumstances of the fall and a complete history and physical examination, looking for potential risk factors. The most effective fall prevention strategies are multifactorial interventions targeting identified risk factors, exercises for muscle strengthening combined with balance training, and withdrawal of psychotropic medication. Home hazard assessment and modification by a health professional also is helpful.
Sujet(s)
Chutes accidentelles/prévention et contrôle , Personne âgée fragile , Gériatrie/méthodes , Prévention primaire/méthodes , Chutes accidentelles/mortalité , Chutes accidentelles/statistiques et données numériques , Accidents domestiques/mortalité , Accidents domestiques/prévention et contrôle , Accidents domestiques/statistiques et données numériques , Activités de la vie quotidienne , Sujet âgé , Sujet âgé de 80 ans ou plus , Algorithmes , Causalité , Arbres de décision , Médecine factuelle , Personne âgée fragile/statistiques et données numériques , Évaluation gériatrique/méthodes , Gériatrie/normes , Humains , Recueil de l'anamnèse/méthodes , Examen physique/méthodes , Guides de bonnes pratiques cliniques comme sujet , Prévention primaire/normes , Appréciation des risques , Gestion du risque , Gestion de la sécuritéRÉSUMÉ
Impaired glucose tolerance and impaired fasting glucose form an intermediate stage in the natural history of diabetes mellitus. From 10 to 15 percent of adults in the United States have one of these conditions. Impaired glucose tolerance is defined as two-hour glucose levels of 140 to 199 mg per dL (7.8 to 11.0 mmol) on the 75-g oral glucose tolerance test, and impaired fasting glucose is defined as glucose levels of 100 to 125 mg per dL (5.6 to 6.9 mmol per L) in fasting patients. These glucose levels are above normal but below the level that is diagnostic for diabetes. Patients with impaired glucose tolerance or impaired fasting glucose have a significant risk of developing diabetes and thus are an important target group for primary prevention. Risk factors for diabetes include family history of diabetes, body mass index greater than 25 kg per m2, sedentary lifestyle, hypertension, dyslipidemia, history of gestational diabetes or large-for-gestational-age infant, and polycystic ovary syndrome. Blacks, Latin Americans, Native Americans, and Asian-Pacific Islanders also are at increased risk for diabetes. Patients at higher risk should be screened with a fasting plasma glucose level. When the diagnosis of impaired glucose tolerance or impaired fasting glucose is made, physicians should counsel patients to lose 5 to 7 percent of their body weight and engage in moderate physical activity for at least 150 minutes per week. Drug therapy with metformin or acarbose has been shown to delay or prevent the onset of diabetes. However, medications are not as effective as lifestyle changes, and it is not known if treatment with these drugs is cost effective in the management of impaired glucose tolerance.
Sujet(s)
Syndrome métabolique X/diagnostic , État prédiabétique/diagnostic , État prédiabétique/thérapie , Glycémie/analyse , Diabète/épidémiologie , Diabète/prévention et contrôle , Diabète gestationnel/épidémiologie , Évolution de la maladie , Femelle , Intolérance au glucose/diagnostic , Hyperglycémie provoquée , Humains , Hypoglycémiants/usage thérapeutique , Mode de vie , Metformine/usage thérapeutique , Grossesse , Facteurs de risqueRÉSUMÉ
Slow reduction in infant mortality rate in the last couple of decades is a major concern in India. State-level aggregate data from the National Family Health Survey 1992 and micro-level data on rural mothers (n=317) were used for examining the influence of female literacy on reduction of infant mortality through increased use of maternal and child health (MCH) services. Illiteracy of females was strongly associated with all variables relating to maternal care and also with infant mortality rate. States were grouped into best, medium, and worst on the basis of female illiteracy (about 11%, 48.5%, and 75% respectively). Infant mortality rate (per 1,000 livebirths) was significantly (p<0.01) higher among the worst group (90.99) than that among the medium (64.2) and the best (24.0) groups. Use of maternal health services increased in the worst to become the best groups for tetanus toxoid (from 48.0% to 84.4%), iron and folic acid tablets (36.6% to 76.2%), hospitalized deliveries (14.2% to 69.7%), and childcare services, such as vaccination (23.8% to 64.9%). Illiteracy of females had a more detrimental impact on rural than on urban areas. In the event of high female illiteracy, male literacy was beneficial for improving the use of services for reducing infant mortality rate. The micro-level study supported all major findings obtained for the national-level aggregate data. Programmes, like providing free education to girls, will yield long-term health benefits.